Eli Lilly's Next-Generation Obesity Drug Reduces Body Weight by 28%

The news highlights Eli Lilly's success with its obesity drug, which serves as a positive catalyst for the stock. Technical indicators also point to a strong uptrend: the RSI is approaching overbought territory at 68.6 but maintains momentum, the MACD is above its signal line and positive, and the price is trading above its 20- and 50-day moving averages, having gained 5.6% in the last 24 hours. The short-term uptrend is expected to continue, though the RSI's proximity to overbought levels suggests a risk of some profit-taking.

The news focuses on Eli Lilly's obesity drug and does not directly affect GOOGL. Technical indicators show the stock trading below its short-term SMA20, with an RSI of 44 in neutral territory. The MACD is below the signal line but the gap is narrowing, which could signal a weak recovery. Despite a 2.7% decline in the last close, there is no clear directional signal. Therefore, a sideways movement is expected in the short term.